As of Aug 21
| -0.05 / -3.82%|
The 3 analysts offering 12-month price forecasts for Aevi Genomic Medicine Inc have a median target of 5.00, with a high estimate of 7.00 and a low estimate of 1.50. The median estimate represents a +296.83% increase from the last price of 1.26.
The current consensus among 3 polled investment analysts is to Buy stock in Aevi Genomic Medicine Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.